ZENITH
Sotatercept in High-Risk Pulmonary Arterial Hypertension
Paciente / Población Intervención / Exposición Comparación Desenlace
In 172 patients with high-risk pulmonary arterial hypertension, sotatercept reduced death, lung transplantation or heart-failure hospitalisation compared with placebo.
N
172
Diseño
Double-blind RCT, stopped early
Desenlace
Death, lung transplant or PAH hospitalisation
Relevancia
2
ResultadoHR 0.24 (76 % reduction in the primary composite).
Humbert M, et al. N Engl J Med. 2025;392(20):1987-2000. 10.1056/NEJMoa2415160
Discusión y crítica
Confirmed a hard-outcome benefit in the sickest PAH patients (functional class III–IV). Small and stopped early, which can inflate the effect estimate.